We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.
Apligraf® Insurance Coverage.Apligraf® InsuranceApligraf® Patient Assistance Program

Organogenesis is committed to providing access to Apligraf® for those most in need through The Apligraf® Patient Assistance Program. This program can assist patients with limited financial resources who also have no public or private insurance coverage.

To be eligible for this Program, the patient must:

  1. Be a U.S. resident
  2. Supply proof of income (1040 Tax Form or SSI statement along with application completed and signed)
  3. Have no public or private insurance coverage – this program is not a co-payment assistance program

Please note that eligibility is determined on a case-by-case basis. Please apply with the assistance of your health care professional who is treating you.

Please print and have your healthcare professional fill out the Apligraf® Patient Assistance Program Application
and fax to: 1-866-212-2888.

References:

3. Falanga V, Sabolinski ML. A bilayered living skin construct (Apligraf®) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201-207.

4. Veves A, Falanga V, et al. Graftskin, a human skin equivalent, is effective in management of non-infected neuropathic diabetic foot ulcers. Diabetes Care. 2001;24:290-295